These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37086156)

  • 41. Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.
    Minemura H; Takagi K; Sato A; Yamaguchi M; Hayashi C; Miki Y; Harada-Shoji N; Miyashita M; Sasano H; Suzuki T
    Breast Cancer; 2021 Jul; 28(4):915-926. PubMed ID: 33713004
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
    Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
    J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Function and expression of yeast mitochondrial NAD- and NADP-specific isocitrate dehydrogenases.
    Haselbeck RJ; McAlister-Henn L
    J Biol Chem; 1993 Jun; 268(16):12116-22. PubMed ID: 8099357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway.
    Zhang L; Qi M; Feng T; Hu J; Wang L; Li X; Gao W; Liu H; Jiao M; Wu Z; Bai X; Bie Y; Liu L; Han B
    Neoplasia; 2018 Feb; 20(2):207-217. PubMed ID: 29331887
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comprehensive Metabolomic Analysis of IDH1
    Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
    Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.
    Cuyàs E; Fernández-Arroyo S; Corominas-Faja B; Rodríguez-Gallego E; Bosch-Barrera J; Martin-Castillo B; De Llorens R; Joven J; Menendez JA
    Oncotarget; 2015 May; 6(14):12279-96. PubMed ID: 25980580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
    Hu WY; Xu L; Chen B; Ou S; Muzzarelli KM; Hu DP; Li Y; Yang Z; Vander Griend DJ; Prins GS; Qin Z
    Prostate; 2019 Jul; 79(10):1166-1179. PubMed ID: 31135075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Unraveling the Peculiar Features of Mitochondrial Metabolism and Dynamics in Prostate Cancer.
    Fontana F; Anselmi M; Limonta P
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity.
    Desideri E; Vegliante R; Ciriolo MR
    Cancer Lett; 2015 Jan; 356(2 Pt A):217-23. PubMed ID: 24614286
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.
    Wise DR; Ward PS; Shay JE; Cross JR; Gruber JJ; Sachdeva UM; Platt JM; DeMatteo RG; Simon MC; Thompson CB
    Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19611-6. PubMed ID: 22106302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2.
    Zhao R; Feng T; Gao L; Sun F; Zhou Q; Wang X; Liu J; Zhang W; Wang M; Xiong X; Jia W; Chen W; Wang L; Han B
    J Exp Clin Cancer Res; 2022 Apr; 41(1):125. PubMed ID: 35382861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Revisiting the TCA cycle: signaling to tumor formation.
    Raimundo N; Baysal BE; Shadel GS
    Trends Mol Med; 2011 Nov; 17(11):641-9. PubMed ID: 21764377
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
    Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
    Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
    Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
    Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression patterns of members of the isocitrate dehydrogenase gene family in murine inner ear.
    Kim YR; Kim KH; Lee S; Oh SK; Park JW; Lee KY; Baek JI; Kim UK
    Biotech Histochem; 2017; 92(7):536-544. PubMed ID: 28925723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isolation of a Histoplasma capsulatum cDNA that complements a mitochondrial NAD(+)-isocitrate dehydrogenase subunit I-deficient mutant of Saccharomyces cerevisiae.
    Johnson CH; McEwen JE
    Yeast; 1999 Jun; 15(9):799-804. PubMed ID: 10398348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gluconeogenic precursor availability regulates flux through the glyoxylate shunt in
    Crousilles A; Dolan SK; Brear P; Chirgadze DY; Welch M
    J Biol Chem; 2018 Sep; 293(37):14260-14269. PubMed ID: 30030382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.
    Fujiwara H; Tateishi K; Misumi K; Hayashi A; Igarashi K; Kato H; Nakatsuka T; Suzuki N; Yamamoto K; Kudo Y; Hayakawa Y; Nakagawa H; Tanaka Y; Ijichi H; Kogure H; Nakai Y; Isayama H; Hasegawa K; Fukayama M; Soga T; Koike K
    Sci Rep; 2019 Dec; 9(1):18859. PubMed ID: 31827136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.